Biofrontera AG (FRA:B8FK)

Germany flag Germany · Delayed Price · Currency is EUR
2.710
+0.050 (1.88%)
Last updated: Sep 29, 2025, 5:36 PM CET
1.88%
Market Cap16.47M
Revenue (ttm)23.72M
Net Income (ttm)-964.00K
Shares Outn/a
EPS (ttm)-0.13
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume109
Average Volume52
Open2.620
Previous Close2.660
Day's Range2.600 - 2.710
52-Week Range2.010 - 3.185
Betan/a
RSI52.05
Earnings DateSep 30, 2025

About Biofrontera AG

Biofrontera AG, a biopharmaceutical company, engages in the research, development, and distribution of dermatological products in Germany, Spain, the United Kingdom, rest of Europe, the United States, and internationally. The company offers Ameluz and BF-RhodoLED lamp for the treatment of mild and moderate actinic keratoses on the face and scalp, field cancerization, and fatal squamous cell carcinoma. It also provides RhodoLED XL lamp for the treatment of multiple interspersed lesions; and Belixos, a cosmetic product for irritated and sensitive... [Read more]

Industry Pharmaceutical Preparations
Founded 1997
Employees 88
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol B8FK
Full Company Profile

Financial Performance

In 2024, Biofrontera AG's revenue was 21.67 million, a decrease of -32.81% compared to the previous year's 32.25 million. Losses were -4.35 million, 1078.9% more than in 2023.

Financial Statements

News

There is no news available yet.